CompletedNCT04038957

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

Medication studyAges 18–45United Kingdom

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Study clarity

Study start dateStarted: August 7, 2019

Recruitment status: Completed
Enrollment listed in the registry: 22
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United Kingdom
Age range: From 18 Years to 45 Years
Official registry ID: NCT04038957
Official title: Show the full official title
An Open-Label Positron Emission Tomography Study to Investigate the Effect of Adjunctive Administration of SEP-363856 on Brain Dopamine Synthesis Capacity Using 18F-DOPA in Adult Subjects With Schizophrenia

Completed

London

FAQ

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including SEP-363856.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.